Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome
Mercoledì 26 aprile 2023
circa 1 minuti di lettura
Journal and Affiliations:
Canadian Journal of Cardiology, 26 aprile 2023
Marco Valgimigli, Cardiocentro Ticino, EOC, Lugano
Tags:
acute coronary syndrome
alirocumab
major adverse cardiovascular events
revascularization
Authors:
Marco Valgimigli